프로트롬빈 복합체 농축 제제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2032년)

The global demand for Prothrombin Complex Concentrate Market is presumed to reach the market size of nearly USD 910.94 Million by 2032 from USD 855.51 Million in 2023 with a CAGR of 0.7% under the study period 2024-2032.

Prothrombin complex concentrate is a hemostatic blood product used as medication. It is made up of blood clotting factors II, IX, X, and sometimes factor VII. This concentrate has the ability to reverse the effects of warfarin and other vitamin K anticoagulants. It is used in significant bleeding cases in people with coagulopathy or when such patients undergo an emergency operation treatment. It is also used in people with a deficiency of one of the clotting factors because of congenital, liver disease, or hemophilia. It is administered using a slow injection directly into the human vein. It is produced by the ion-exchange chromatography of the cryoprecipitate supernatant of large plasma pools and antithrombin and factor XI removal.

MARKET DYNAMICS

The increased prevalence of bleeding disorders and eased government approval for innovative medical therapies are few driving factors favoring the market growth. The rising demand for PCC for treating unwanted excessive bleeding during surgical procedures due to its high clinical efficiency will benefit the market's growth. The growing use of warfarin therapy and the high efficiency of prothrombin complex concentrates in rapidly reversing coagulopathy in patients with warfarin-related intracranial hemorrhage will enhance the market growth. Increased investments in the research and development of new drugs to treat blood clotting disorders and improving healthcare infrastructure will be a market booster. Lack of awareness and the side effects of these medications can have a burdening impact on market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Prothrombin Complex Concentrate. The growth and trends of Prothrombin Complex Concentrate industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Prothrombin Complex Concentrate market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• 3-factor PCC
• 4-factor PCC

By Application

• Acquired Coagulation Factor Deficiency
• Congenital Coagulation Factor Deficiency
• Others

By End-use

• Hospital & Ambulatory Surgical Centers
• Specialty Clinics
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Prothrombin Complex Concentrate market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Prothrombin Complex Concentrate market include CSL, Octapharma AG, Kedrion, Takeda Pharmaceutical Company Limited., Taibang Biological Group Co. Ltd., Sanquin, Grifols, S.A., Biotest AG, Abeona Therapeutics Inc., Insud Pharma. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. PROTHROMBIN COMPLEX CONCENTRATE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By End-use
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Product
• 5.4. 3-factor PCC Historic and Forecast Sales By Regions
• 5.5. 4-factor PCC Historic and Forecast Sales By Regions

6. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY APPLICATION

• 6.1. Overview By Application
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Application
• 6.4. Acquired Coagulation Factor Deficiency Historic and Forecast Sales By Regions
• 6.5. Congenital Coagulation Factor Deficiency Historic and Forecast Sales By Regions
• 6.6. Others Historic and Forecast Sales By Regions

7. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY END-USE

• 7.1. Overview By End-use
• 7.2. Historical and Forecast Data
• 7.3. Analysis By End-use
• 7.4. Hospital & Ambulatory Surgical Centers Historic and Forecast Sales By Regions
• 7.5. Specialty Clinics Historic and Forecast Sales By Regions
• 7.6. Others Historic and Forecast Sales By Regions

8. GLOBAL PROTHROMBIN COMPLEX CONCENTRATE MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE PROTHROMBIN COMPLEX CONCENTRATE COMPANIES

• 9.1. Prothrombin Complex Concentrate Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF PROTHROMBIN COMPLEX CONCENTRATE INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. CSL
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Octapharma AG
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Kedrion
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Takeda Pharmaceutical Company Limited.
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Taibang Biological Group Co. Ltd.
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Sanquin
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Grifols
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. S.A.
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Biotest AG
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Abeona Therapeutics Inc.
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments
• 10.13. Insud Pharma
  • 10.13.1 Company Overview
  • 10.13.2 Company Revenue
  • 10.13.3 Products
  • 10.13.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies